MannKind Corporation today announced positive preliminary results from Study 171, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind’s next-generation (Gen2) inhaler, in patients with type 1 diabetes.

Roche announced that Lucentis ( ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema ( DME ), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness.

Nearly 26 million Americans have diabetes, and another 79 million have prediabetes. That's about 30 percent of all Americans with a diabetes problem.